CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Serum testingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1570 Nasal swab Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers

The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune response and its protective effect as well as the assessment of infectivity of affected HCWs and 4) to evaluate the value and significance of antibody formation and serological antibody tests and 5) to be able to evaluate possible future preventive and / or therapeutic approaches against SARS-CoV-2

NCT04370119 SARS-Cov-2 Diagnostic Test: Nasal swab Diagnostic Test: Serum testing
MeSH:Infection

Primary Outcomes

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 1 year

Secondary Outcomes

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 1 year

Other Outcomes

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 2 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 3 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 4 years

Description: Anti-SARS-COV2 S protein IgG ELISA

Measure: Number of people with detectable antibodies to SARS-COV2

Time: 5 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 2 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 3 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 4 years

Description: SARS-COV2 PCR

Measure: Number of people with detectable SARS-COV2 nucleic acid

Time: 5 years


No related HPO nodes (Using clinical trials)